The Floor Is Shifting Under Mammography. Most Program Leaders Don't Know It Yet.

Published by Richard D. Lippert Jr., Founder & Owner, Mammologix, Inc. | May 2026

---

Most breast imaging program leaders are not in the business of tracking federal policy. That is understandable. Clinical operations are demanding, and regulatory monitoring rarely feels urgent until something goes wrong. But the systems that support women's access to quality mammography are, right now, under more stress than at any point in the past decade.

This is not about politics. The pressures described here predate the current news cycle and will outlast it. Four distinct forces are in motion simultaneously, and their combined effect on breast imaging programs deserves the attention of anyone responsible for program quality and financial sustainability.

Here is a plain account of each.

---

1. The USPSTF Has Not Met in Over a Year. That Has Real Coverage Consequences.

The U.S. Preventive Services Task Force is the independent expert panel whose recommendations determine which preventive services must be covered by insurers at no cost to patients, under Section 2713 of the Affordable Care Act. In 2024, the Task Force updated its breast cancer screening recommendation to Grade B, supporting biennial screening (every two years) for average-risk women ages 40 to 74.[1] Under the ACA, that Grade B rating legally requires insurers to eliminate cost-sharing for covered mammography services.

One clarification is worth making here, because confusion on this point is common. The USPSTF biennial recommendation is the coverage mandate floor. It is not the clinical standard. The American College of Radiology, the Society of Breast Imaging, and the American Society of Breast Surgeons each recommend annual screening beginning at age 40, based on evidence that annual screening produces the greatest reduction in breast cancer mortality and the most life-years gained.[2] Both positions matter: the USPSTF standard governs what insurers must cover; the specialty organization standard reflects the clinical goal programs should be working toward.

Now for the problem. The Task Force typically meets three times a year. It has not met since March 2025. HHS canceled the July 2025 meeting. The November 2025 meeting did not take place. The March 2026 meeting was postponed a third time.[3] No date has been set for the next meeting.

This matters for coverage because the Task Force's administrative support sits within the Agency for Healthcare Research and Quality, which faces significant budget and structural pressure under current HHS reorganization proposals.[4] More significantly, a Supreme Court ruling issued in June 2025 confirmed that the HHS Secretary holds supervisory authority over the panel's composition and operations.[5] The ruling upheld the constitutionality of the ACA preventive services mandate, which is the good news. The concern is the confirmation that the panel's independence from executive influence is institutional rather than statutory. An executive branch willing to restructure other federal advisory bodies has the legal tools to do the same here.

The short version: the coverage mandate that protects your patients' no-cost access to mammography is legally intact today. Whether it remains unchanged depends on a panel that has not convened in over a year and whose independence is now a matter of policy rather than law.

---

2. MQSA Is Federal Law. But Its Enforcement Is Worth Watching.

Let me be direct about something: MQSA is not going away. The Mammography Quality Standards Act of 1992 is a statute.[6] Executive action cannot repeal it. The requirement that all mammography facilities be accredited, certified, and inspected annually is codified law, and it will remain so.

The question worth asking is not whether MQSA survives, but whether its enforcement apparatus maintains the consistency that gives the statute its practical force. As of October 2024, 8,931 facilities held active certification, with FDA reporting 8,963 certified facilities by March 2025.[7] Annual inspection of that population requires staffing, budget, and institutional continuity within FDA's Center for Devices and Radiological Health. HHS announced significant FDA workforce reductions in early 2025, with official statements indicating that medical device reviewers and inspectors were among exempted categories.[8] That distinction matters and should not be dismissed.

Still, the broader reorganization of HHS warrants sustained attention rather than assumption that nothing will change. History is instructive here. In MQSA's first year of enforcement, 26% of facilities had significant violations on initial inspection. The improvement that followed was driven almost entirely by the consistent, credible threat of inspection with real consequences. Reduce that credibility and the quality floor drifts, regardless of what the statute says.

The appropriate response is simple: treat MQSA compliance as a continuous obligation, not an inspection-period exercise. The 2023 Final Rule amendments are in full effect. Personnel qualification records, breast density notification documentation, and medical outcomes audit standards all require sustained attention. Do not wait to be inspected to find out where you stand.

---

3. The Cultural Environment Is Moving in a Direction That Could Affect Screening Behavior.

There is a strand in current health policy discourse that treats organized, population-level clinical screening programs as examples of medical overreach: costly interventions driven by institutional incentives rather than genuine patient benefit. Mammography is not the primary target of this narrative today. The focus is largely on vaccines, pharmaceutical prescribing, and pediatric medicine.

But the intellectual framework is there. For a decade, a subset of the academic literature has argued that mammography produces meaningful overdiagnosis: the detection of breast cancers that would never have caused harm if left undetected.[9] This is a legitimate scientific debate. The American Cancer Society acknowledges overdiagnosis as a possible harm while continuing to support screening for average-risk women.[10] The ACR and leading breast imaging researchers have argued that published overdiagnosis estimates are methodologically flawed and that the mortality benefit of organized screening is strong and well-documented.[11] That argument is correct. The data support it.[12]

The risk is not that the science changes. It is that this debate gets simplified and amplified by non-clinical voices in a political environment already primed to distrust organized medicine. Women who encounter credible-sounding messaging that questions whether their annual mammogram is worth it — and who also face new cost-sharing barriers because of what is happening to USPSTF — have rational reasons to skip or delay screening. The mortality consequences of that pattern are well-documented.

This is a behavioral threat, not a regulatory one. It requires a communication response, not a compliance one.

---

4. These Three Threats Reinforce Each Other. That Is the Real Problem.

Considered separately, each of the above risks is manageable. Taken together, they form a cascade that is harder to interrupt.

USPSTF disruption creates uncertainty about the coverage mandate. Coverage uncertainty gives insurers reason to reintroduce cost-sharing. Cost-sharing reduces patient compliance with screening, particularly among lower-income populations.[13] A cultural narrative that rationalizes skipping screening accelerates that compliance drop. Reduced screening volume weakens program revenue. Weakened programs cut infrastructure. Reduced infrastructure increases compliance risk. And a facility that reaches that point during a period of uncertain MQSA enforcement is in real trouble.

The programs most exposed to this sequence are those with thin margins, limited payer diversity, and patient populations where cost historically suppresses utilization. Rural programs and safety-net facilities carry the greatest structural risk. But no program is fully immune.

---

What to Do Now

None of this calls for panic. It calls for preparation.

1. Run a compliance audit against the 2023 Final Rule requirements now, without waiting for an inspection. Know exactly where you stand on breast density notification, personnel qualification currency, and medical outcomes audit documentation.

2. Understand both screening standards and use them correctly. The USPSTF biennial recommendation governs what insurers must cover.[14] The ACR/SBI/ASBrS annual recommendation is the clinical target.[15] Use coverage-mandate language with payers and billing operations; use the clinical standard with referring providers and patients.

3. Map your payer exposure. Know which insurers drive your volume, what their current cost-sharing terms are for mammography, and what a 10 to 15 percent volume reduction would mean for program sustainability.

4. Brief your referring providers on the evidence for annual screening beginning at age 40. The ACR, SBI, and ASBrS have each published clear position statements. Every clinician in your referral network should be able to articulate this case to patients.

5. Watch USPSTF developments actively. A coverage disruption discovered months after the fact is a coverage disruption that has already cost you volume.

---

In our work with approximately 200 breast imaging programs across the eastern, southeastern, and southwestern United States, we track MQSA compliance, mammographic medical outcomes auditing, and clinical performance across a broad and varied population of facilities. The conditions described in this article are visible from that vantage point in ways that may not be apparent from within a single program. We will continue reporting on developments that matter to program leadership.

The standard of care in breast imaging is worth protecting. It starts with knowing what is working against it.

---

References

1. U.S. Preventive Services Task Force. Screening for Breast Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2024;331(22):1918–1930. doi:10.1001/jama.2024.5534
2. Monticciolo DL, Malak SF, Friedewald SM, et al. Breast Cancer Screening Recommendations Inclusive of All Women at Average Risk: Update from the ACR and Society of Breast Imaging. J Am Coll Radiol. 2021;18(9):1280–1288. doi:10.1016/j.jacr.2021.04.021
3. Reuters/NBC News. U.S. Preventive Services Task Force Meeting Postponed for Third Consecutive Time. March 3, 2026.
4. U.S. Department of Health and Human Services. FY2026 Budget in Brief. HHS.gov; 2025.
5. Kennedy v. Braidwood Management, Inc., No. 24-316 (U.S. June 27, 2025).
6. Mammography Quality Standards Act of 1992. Pub. L. No. 102-539, 42 U.S.C. § 263b (1992).
7. U.S. Food and Drug Administration. MQSA National Statistics. CDRH; October 1, 2024 and March 1, 2025.
8. U.S. Department of Health and Human Services. HHS Organizational Modernization: FDA Workforce Restructuring Fact Sheet. 2025.
9. Welch HG, Black WC. Overdiagnosis in Cancer. J Natl Cancer Inst. 2010;102(9):605–613. doi:10.1093/jnci/djq099
10. American Cancer Society. Breast Cancer Screening Guidelines for Women at Average Risk. ACS; revised 2023.
11. Monticciolo DL, Newell MS, Moy L, Niell B, Monsees B, Sickles EA. Breast Cancer in Women at Higher-Than-Average Risk: Recommendations From the ACR. J Am Coll Radiol. 2018;15(3 Pt A):408–414. doi:10.1016/j.jacr.2017.11.034
12. Coldman A, Phillips N, Wilson C, et al. Pan-Canadian Study of Mammography Screening and Mortality from Breast Cancer. J Natl Cancer Inst. 2014;106(11):dju261. doi:10.1093/jnci/dju261
13. Wharam JF, Zhang F, Landon BE, Soumerai SB, Ross-Degnan D. Low-Socioeconomic-Status Enrollees in High-Deductible Plans Reduced High-Value Care. Health Aff. 2013;32(8):1398–1406. doi:10.1377/hlthaff.2012.1027
14. Patient Protection and Affordable Care Act. Pub. L. No. 111-148, § 2713, 42 U.S.C. § 300gg-13 (2010).
15. American Society of Breast Surgeons. Position Statement on Screening Mammography. Approved April 6, 2026.

---

BI-RADS® is a registered trademark of the American College of Radiology. Its use in this article is for educational and informational purposes only.